Chronic Myelogenous Leukemia

Alfonso Quintás-Cardama, Jorge Cortes, Hagop Kantarjian, Susan O'Brien

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations
Original languageEnglish (US)
Title of host publicationMolecular Hematology
Subtitle of host publicationThird Edition
PublisherWiley-Blackwell
Pages76-88
Number of pages13
ISBN (Print)9781405182317
DOIs
StatePublished - Mar 10 2010
Externally publishedYes

Keywords

  • BCR-ABL 1 kinase signaling pathways
  • BP CML, characterized by prominent hypercatabolic symptoms
  • Chronic myelogenous leukemia
  • Chronic myeloid leukemia (CML), clonal myeloproliferative neoplasm from pluripotent stem cell
  • Emergence of imatinib mesylate -change in therapeutic algorithm for CML
  • Genome-wide analyses of gene expression profiles -prognostication tools in multiple malignancies
  • Imatinib resistance -categorized as primary (also "refractoriness")
  • Signaling pathways activated by BCR-ABL1 kinase
  • Stem cell transplantation -allogeneic SCT, therapeutic modality for patients with human leukocyte antigen (HLA)-identical siblings

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Quintás-Cardama, A., Cortes, J., Kantarjian, H., & O'Brien, S. (2010). Chronic Myelogenous Leukemia. In Molecular Hematology: Third Edition (pp. 76-88). Wiley-Blackwell. https://doi.org/10.1002/9781444318531.ch7